Walking Away From JNJ

OCTOBER 20, 2019. Looking for trouble is unneeded. Plenty exists.
We’ve warned against one since August 29th. It’s glowed right before us, everyday. JNJ, and it proved that trouble, clinically. On October 11, Bernstein analyst Lee Hambright charmed JNJ with an upgrade to “Outperform,” and a price target of $155. Seven days later shares dropped -6.22% on greater than triple volume. Why? FDA testing revealed asbestos contamination in its” baby powder. That came right on the heels of the massive judgment against the company for it’s antipsychotic Risperdal, creating a new nightmarish third legal front. That judgment was for $8 billion, for one individual.
Meanwhile, the company suggested it was “open” to a collective settlement of thousands of looming lawsuits relating to its’ part in the opioids plague. And in the foreground Purdue Pharma is being eviscerated on the very same charges. This month comes the start in Ohio of the first federal-level opioids case.
New Brunswick-based Johnson & Johnson has for decades been viewed as a cozy haven of stability and payouts to investors in all markets. Besides the Bernstein upgrade, eight days ago Barron’s named it as one of its’ five best dividend plays. For now JNJ will be more known as a defendant, on multiple fronts. Their payouts in the future will look very different. “Walking Away From JNJ.”
Continue reading Walking Away From JNJ